Wyeth

Tania Shane

Kevin Delos Parris

Jose William Saldanha

Geertruida Machteld Veldman

Lioudmila Tchistiakova

Samuel Goldman

Debra D Donaldson

Kimberly Ann Marquette

Xiang-Yang Tan

Lori J Fitz

Angela Widom

Eric Feyfant

Laura Lin

Marion T Kasaian

Amy Sze Pui Tam

Nancy L Wood

Mark L Stahl

Lidia Mosyak

Kathryn W Underwood

Kristine Svenson

Meggin L Taylor

This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.

Antibodies against human interleukin-13 and uses therefor

Antibodies against human interleukin-13 and pharmaceutical compositions thereof

This invention is directed to the crystal structures of MK2, and to the use of these structures in rational drug design methods to identify agents that may interact with active sites of MK2 proteins. Such agents may be useful as therapeutic agents.

Methods for identifying agents that interact with MAP kinase activated protein kinase 2

Growing community of inventors

Newton, MA, United States of America

Tania Shane